Adragos Pharma, a global Contract Development and Manufacturing Organization (CDMO) headquartered in Munich, has announced the acquisition of Baccinex, a Swiss leader in aseptic fill-finish and lyophilization technologies. This acquisition significantly boosts Adragos Pharma’s capacity in sterile drug production and enhances its competitiveness in the global pharmaceutical market.

Baccinex, based in Courroux, Jura, Switzerland, has over 20 years of expertise in manufacturing sterile liquid and lyophilized drug products. Specializing in clinical trial supplies and small- to medium-scale commercial production, the company operates state-of-the-art facilities that meet both EU GMP and U.S. FDA standards.

Leadership Insights
Dr. Ursula Bausch, CEO and Founder of Baccinex, commented:
"Joining Adragos Pharma marks an exciting new chapter, enabling us to expand the reach of our sterile manufacturing expertise. Our shared commitment to quality, innovation, and client-centric solutions promises to create synergies that deliver greater value to clients worldwide."

Dr. Andreas Raabe, CEO and Founder of Adragos Pharma, stated:
"The acquisition of Baccinex is a pivotal step in expanding our expertise in aseptic liquids and lyophilization. By integrating Baccinex’s technical strengths and operational excellence, we will provide comprehensive solutions spanning clinical trials to commercial production, solidifying our position as a trusted global partner in pharmaceutical manufacturing."

Dr. Bausch will continue to lead Baccinex as its CEO and remain a shareholder, reinforcing the company’s commitment to advancing sterile drug manufacturing as part of the Adragos Pharma Group.

Strategic Growth and Long-Term Vision
This acquisition aligns with Adragos Pharma’s long-term strategy to address evolving client needs and build a robust global manufacturing network in sterile liquids and lyophilization. Baccinex becomes the sixth manufacturing site within Adragos Pharma’s network, contributing to the company’s ability to meet growing global demand for clinical and commercial pharmaceutical production.

Legal and Financial Advisors
Adragos Pharma was advised by Pestalozzi Attorneys at Law and Capitalmind Investec for legal and M&A advisory services, while Dr. Bausch was represented by Kellerhals Carrard. Transaction terms remain confidential, adhering to customary practices.